Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated)

For adults aged 18 to 64 years, the standard dosage of the vaccine containing the Influenza B Virus B/phuket/3073/2013 Antigen is a single 0.5 mL intramuscular injection. This dose typically contains 15 mcg of the hemagglutinin antigen for this specific strain, along with 15 mcg each of three other strains (two Influenza A strains and one other Influenza B strain).

For adults aged 65 years and older, a 'High-Dose' version may be administered. This version contains 60 mcg of the B/phuket/3073/2013 antigen per 0.7 mL dose. Clinical trials have demonstrated that this higher concentration of antigen is necessary to elicit a protective immune response in the elderly population, who may not respond as robustly to the standard dose.

Influenza B Virus B/phuket/3073/2013 Antigen is approved for use in pediatric populations as young as 6 months of age. The dosing schedule depends on the child's age and previous vaccination history:

• Children 6 months through 8 years: If the child has not previously received at least two doses of influenza vaccine before July 1st of the current year, they require two doses, administered at least 4 weeks apart. Each dose is typically 0.5 mL. If they have a history of prior vaccination, a single 0.5 mL dose is sufficient.
• Children 9 years and older: A single 0.5 mL dose is administered annually.

It is critical to ensure that the specific vaccine brand used is FDA-approved for the child's specific age group, as some formulations are only approved for those 3 years or older.

Renal Impairment

No dosage adjustment is required for patients with renal impairment. Because the antigen is not cleared by the kidneys in its active form and does not exert systemic pharmacological effects, the safety profile remains unchanged in this population.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic impairment. The liver does not play a role in the primary processing of the vaccine antigen.

Elderly Patients

As noted, patients 65 and older should ideally receive the High-Dose (HD) or Adjuvanted (containing MF59) formulations to ensure adequate antibody production. Standard doses are safe but may be less effective.

This medication is administered exclusively by a healthcare professional. It is given as an intramuscular (IM) injection. In adults and older children, the preferred site is the deltoid muscle of the upper arm. In infants and small children, the anterolateral aspect of the thigh (vastus lateralis) is the preferred site due to larger muscle mass.

• Preparation: The vial or syringe should be shaken well before administration to ensure a uniform suspension. It should be inspected visually for particulate matter or discoloration.
• Food/Drink: There are no restrictions regarding food or drink before or after the injection.
• Storage: The vaccine must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It must NEVER be frozen. Exposure to freezing temperatures destroys the immunogenicity of the antigen.

Because the influenza vaccine is typically an annual single-dose treatment, a 'missed dose' refers to failing to get vaccinated during the flu season. If a child requires two doses and misses the second, the second dose should be administered as soon as possible, provided the flu season is still ongoing.

An overdose is highly unlikely as the medication is administered by a healthcare professional in a pre-measured dose. However, if an accidental double dose occurs, the primary risk is an increase in the severity of local injection site reactions (pain, swelling). No systemic toxicity is expected. In case of error, monitor the patient for 15-30 minutes for any signs of immediate hypersensitivity.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most side effects associated with Influenza B Virus B/phuket/3073/2013 Antigen are mild and resolve within 24 to 48 hours. These are often signs that the immune system is responding to the antigen. Common reactions include:

• Injection Site Pain: A dull ache or soreness in the deltoid muscle where the shot was given. This affects up to 65% of recipients.
• Erythema (Redness): A small red patch at the injection site, typically less than 1 inch in diameter.
• Induration (Swelling): A localized hardening of the skin at the site of injection.
• Myalgia: General muscle aches throughout the body, similar to the early stages of a cold.
• Malaise: A general feeling of discomfort, fatigue, or 'feeling under the weather.'
• Headache: Mild to moderate tension-type headache.

• Low-grade Fever: A temperature between 100.4°F and 101.5°F, more common in children than adults.
• Chills: Shivering or feeling cold shortly after the injection.
• Nausea: Mild upset stomach or loss of appetite, particularly in pediatric patients.
• Lymphadenopathy: Swelling of the lymph nodes in the armpit (axilla) on the side of the injection.

• Syncope (Fainting): This is often a vasovagal response to the needle rather than the antigen itself, most common in adolescents.
• Urticaria (Hives): A mild allergic skin reaction.
• Paraesthesia: Temporary tingling or 'pins and needles' sensation in the arm.

> Warning: Stop taking Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the throat or tongue, rapid heartbeat, and a sudden drop in blood pressure. This typically occurs within minutes of administration.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system attacks the peripheral nerves. Symptoms include progressive weakness and tingling, usually starting in the legs and moving upward. The estimated risk is approximately 1 to 2 additional cases per million doses administered.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Severe pain and limited range of motion in the shoulder caused by the needle being injected too high or too deep into the joint space rather than the muscle.
• Oculorespiratory Syndrome (ORS): Characterized by red eyes, respiratory symptoms (cough, wheeze), and facial swelling. This was historically associated with specific manufacturing processes but remains a monitored event.

There are no known long-term side effects associated with the B/phuket/3073/2013 antigen. The antigen is cleared from the body within days, and the immune response (antibodies) is the only persisting element. Extensive post-marketing surveillance by the CDC (VAERS) and FDA has not identified any chronic conditions linked to this specific strain.

No FDA black box warnings exist for Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated). It is considered safe for the vast majority of the population when administered according to guidelines.

Report any unusual symptoms to your healthcare provider.

Before receiving a vaccine containing the Influenza B Virus B/phuket/3073/2013 Antigen, it is essential to disclose your full medical history to your healthcare provider. While the antigen is inactivated and cannot cause influenza, certain underlying conditions may increase the risk of adverse events or decrease the effectiveness of the immunization.

No FDA black box warnings for Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of severe allergic reaction (anaphylaxis) to any component of the vaccine, including egg protein (if the vaccine is egg-based), formaldehyde, or antibiotics like neomycin used in the manufacturing process, should not receive the vaccine. Facilities must be equipped with epinephrine and other emergency supplies to treat potential anaphylaxis.
• Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of a previous influenza vaccination, the decision to give this antigen should be based on a careful evaluation of the potential benefits and risks.
• Febrile Illness: Vaccination should typically be deferred in individuals with moderate or severe acute illness, with or without fever. This is to avoid confusing the symptoms of the illness with side effects of the vaccine.
• Immunocompromised Status: Individuals with weakened immune systems (due to HIV, cancer, or immunosuppressive drugs) may have a diminished immune response to the antigen. They may not be fully protected despite vaccination.
• Syncope: Fainting can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to manage syncopal episodes.

There are no specific lab tests (like blood counts or liver function tests) required before or after receiving this antigen. However, patients should be observed for at least 15 minutes post-injection to monitor for immediate allergic reactions.

This antigen has no known effect on the ability to drive or operate machinery. However, if a patient experiences syncope or significant malaise after the injection, they should wait until symptoms resolve before performing these tasks.

There is no direct interaction between alcohol and the Influenza B Virus B/phuket/3073/2013 Antigen. However, excessive alcohol consumption can suppress the immune system and may theoretically reduce the body's ability to generate a robust antibody response.

As this is a single-dose annual medication, 'discontinuation' is not applicable. However, if a patient experiences a severe reaction, they should be 'red-flagged' against receiving vaccines containing this specific strain or related components in the future.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would result in a fatal interaction. However, the following should be avoided:

• Live Attenuated Influenza Vaccine (LAIV): If a patient is receiving the inactivated B/phuket/3073/2013 antigen, they should not simultaneously receive the nasal spray (live) flu vaccine, as this is redundant and increases the risk of side effects without added benefit.

• Immunosuppressive Therapies: Drugs such as high-dose corticosteroids (prednisone >20mg/day), chemotherapy agents, and TNF-inhibitors (e.g., adalimumab, etanercept) can significantly blunt the immune response to the antigen. The clinical consequence is reduced vaccine efficacy, leaving the patient vulnerable to the flu. If possible, vaccination should occur at least 2 weeks before starting immunosuppression or during a 'window' in treatment.
• Anticoagulants: Patients on warfarin, heparin, or DOACs (e.g., apixaban) may experience significant bleeding or hematoma at the injection site. A fine-gauge needle should be used, and firm pressure applied for at least 2 minutes post-injection.

• Statin Medications: Some studies suggest that statins (e.g., atorvastatin) might slightly reduce the antibody titers produced in response to influenza antigens, particularly in the elderly. However, the CDC recommends that patients continue their statin therapy as prescribed.

• Egg Protein: For egg-based vaccines, the presence of trace amounts of ovalbumin is a critical consideration. While the ACIP (Advisory Committee on Immunization Practices) now states that even those with egg allergies can safely receive the vaccine, it must be administered in a medical setting if the allergy is severe.

• High-dose Vitamin C or E: While often taken to 'boost' the immune system, there is no evidence that these interfere with the vaccine. However, very high doses of anti-inflammatory herbs like turmeric (curcumin) could theoretically modulate the initial inflammatory response required for vaccine 'take,' though this is not clinically proven.

• False Positive HIV/HCV/HTLV-1 Tests: There have been rare reports of transient false-positive results in immunoassays for HIV-1, Hepatitis C, and HTLV-1 following influenza vaccination. This is due to the production of cross-reactive IgM antibodies. These false positives usually resolve within 6 weeks and can be clarified with more specific confirmatory tests (e.g., Western blot or PCR).

For each major interaction, the mechanism involves either the pharmacodynamic blunting of the immune system (immunosuppressants) or the physical trauma of the injection (anticoagulants). Management strategies focus on timing and administration technique.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Influenza B Virus B/phuket/3073/2013 Antigen must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis): Any individual who has had a life-threatening reaction to a previous dose of any influenza vaccine or to any specific component of the vaccine (e.g., egg protein, formaldehyde, gelatin, or neomycin) is strictly contraindicated from receiving this antigen. The mechanism is a Type I hypersensitivity reaction mediated by IgE, which can lead to rapid airway obstruction and circulatory collapse.
• Infants under 6 months of age: The safety and efficacy of this antigen have not been established in infants younger than 6 months. Furthermore, maternal antibodies passed during pregnancy may interfere with the infant's ability to mount their own immune response.

• Moderate to Severe Acute Illness: Vaccination should be postponed until the patient has recovered. This prevents the 'masking' of illness symptoms as vaccine side effects and ensures the immune system is not 'distracted' by an active infection.
• History of Guillain-Barré Syndrome (GBS): If a patient developed GBS within 6 weeks of a prior influenza vaccination, they are generally advised to avoid future influenza vaccines unless the risk of severe influenza complications significantly outweighs the risk of recurrent GBS.

Patients with known sensitivities to other Influenza B strains (such as B/Brisbane/60/2008) are likely to be sensitive to the B/phuket/3073/2013 strain due to the similarity in viral proteins. Additionally, because formaldehyde is used in the inactivation process, individuals with a known contact dermatitis allergy to formaldehyde should be monitored, although the trace amounts in the vaccine are usually insufficient to cause a systemic reaction.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated).

Influenza B Virus B/phuket/3073/2013 Antigen is highly recommended for pregnant individuals. Pregnancy is considered a high-risk state for influenza complications due to changes in the immune system, heart, and lungs.

• FDA Category: Historically Category B/C (varies by brand).
• Risks: There is no evidence of teratogenicity (birth defects). Studies involving thousands of pregnant women have shown no increased risk of miscarriage or fetal harm.
• Benefit: Vaccination provides 'passive immunity' to the newborn, as antibodies cross the placenta and protect the infant for several months after birth, a period when they are too young to be vaccinated themselves.

It is safe to receive this antigen while breastfeeding. The inactivated virus cannot enter breast milk, and it cannot infect the nursing infant. However, the protective antibodies produced by the mother can be passed through breast milk (IgA), providing additional protection to the baby.

Approved for children 6 months and older. In children, the antigen is critical for preventing 'influenza-associated encephalopathy,' a rare but devastating brain complication of the flu. Pediatric patients require careful monitoring for fever-induced seizures (febrile seizures) if they have a history of such events, though the risk with this specific antigen is very low.

Adults 65 and older are at the highest risk for hospitalization and death from Influenza B. Due to 'immunosenescence,' the standard dose may not be sufficient. Geriatric patients should receive the High-Dose (HD) formulation of the B/phuket/3073/2013 antigen to ensure protective antibody titers are reached. There is an increased risk of local injection site reactions in this group when using the HD version.

Patients with end-stage renal disease (ESRD) on dialysis often have 'uremic immunodeficiency.' While the vaccine is safe, these patients may require a second dose or a high-dose version to achieve the same level of protection as a healthy adult. This should be discussed with a nephrologist.

Patients with cirrhosis or chronic liver disease are at high risk for secondary bacterial pneumonia following a flu infection. The B/phuket/3073/2013 antigen is safe and strongly recommended for this population to prevent hepatic decompensation triggered by viral illness.

> Important: Special populations require individualized medical assessment.

Influenza B Virus B/phuket/3073/2013 Antigen (uv, Formaldehyde Inactivated) acts as an exogenous antigen. The primary molecular target is the B-cell receptor (BCR) on naive B-lymphocytes. The hemagglutinin (HA) protein on the inactivated virus binds to these receptors, initiating a signaling cascade that leads to clonal expansion and the secretion of antigen-specific antibodies. These antibodies are designed to bind to the 'globular head' of the HA protein of the wild-type virus, blocking the fusion of the viral envelope with the host cell endosomal membrane.

• Dose-Response: There is a clear relationship between the amount of antigen (15 mcg vs 60 mcg) and the resulting Hemagglutination Inhibition (HI) titers. Higher doses generally result in higher seroconversion rates.
• Onset: Protective antibody levels are typically reached 2 to 3 weeks after administration.
• Duration: Immunity typically lasts for 6 to 12 months, which is why annual revaccination is required as antibody levels wane and the virus undergoes 'antigenic drift.'

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life (Antigen) | ~24-48 hours |

| Tmax (Antibody) | 14-21 days |

| Metabolism | Proteolysis |

| Excretion | Renal (as peptides) |

• Molecular Structure: The antigen consists of inactivated viral particles containing segmented negative-sense RNA (denatured) and various structural proteins (HA, NA, M1, NP).
• Formaldehyde Content: Trace amounts (usually <100 mcg per dose), used to cross-link the amino groups of viral proteins.
• Solubility: Formulated as an aqueous suspension.

This agent is a Viral Vaccine Antigen. It is specifically a 'Split-Virus' or 'Subunit' vaccine component, meaning the virus has been disrupted by detergents to reduce reactogenicity while maintaining immunogenicity.